What changed in this filing

/stocks — the workspaceLOADING

Item 3. Legal Proceedings

2025-02-10 compared with 2024-02-13 · 33 added, 23 removed, 77 unchanged (42% of the section changed)

15 unchanged sentences

Hoppenot served in various increasingly senior roles at Aventis S.A.

(formerly Rhône-Poulenc S.A.), a pharmaceutical company, including as Vice President Oncology US of Aventis Pharmaceuticals, Inc.

from 2000 to 2003 and Vice President US Oncology Operations of Rhone-Poulenc Rorer Pharmaceuticals, Inc.

(formerly Rhône-Poulenc S.A.), a pharmaceutical company, including as Vice President Oncology U.S.

of Aventis Pharmaceuticals, Inc.

from 2000 to 2003 and Vice President U.S.

Oncology Operations of Rhone-Poulenc Rorer Pharmaceuticals, Inc.

from 1998 to 2000.

22 unchanged sentences

in Business and Political Science from Sacred Heart University.

Dickinson , age 56, has served as Executive Vice President and General Manager, Europe, since June 2019 and joined Incyte as Senior Vice President and General Manager, Europe in June 2016.

Dickinson joined Incyte from ARIAD Pharmaceuticals (Luxembourg) S.à.r.l, the parent company of ARIAD Pharmaceuticals, Inc.’s European subsidiaries responsible for the development and commercialization of ICLUSIG in the European Union and other countries, where he most recently held the position of Senior Vice President and General Manager, Europe.

Prior to joining ARIAD in February 2013, Mr.

Dickinson served as European oncology brand lead at Bristol-Myers Squibb, a pharmaceutical company, and before that, he held several key leadership positions, including lifecycle leader, during his 13-year tenure at Hoffmann-La Roche, a pharmaceutical company.

At Roche, he had assignments both in the United States and Switzerland that included leadership roles for Roche’s three leading oncology medicines.

Dickinson began his career at Novartis, where he held commercial roles in its oncology and endocrinology businesses, including medical sales, product manager and business director in the United Kingdom.

Dickinson received a B.S.

in Genetics and an M.B.A.

from the University of Nottingham.

Flannelly , age 66, has served as Executive Vice President and General Manager, North America since June 2015 and joined Incyte as Executive Vice President, Business Development and Strategic Planning in August 2014.

Prior to joining Incyte, he served as Chief Executive Officer of OSS Healthcare Inc., a biotechnology start-up company, from August 2013 to July 2014.

He served as Vice President, Global Product Strategy and Commercial Planning of Nektar Therapeutics, a biopharmaceutical company, from April 2011 until April 2013, and as Senior Vice President, Commercial, of Onyx Pharmaceuticals, Inc., a biopharmaceutical company, from August 2008 until January 2011.

Prior thereto, Dr.

Flannelly held key positions at biopharmaceutical and pharmaceutical companies such as Abraxis BioScience, Inc.

and Novartis.

Flannelly earned his doctorate in pharmacy from the University of Maryland, School of Pharmacy, his master’s degree in business administration from the University of Baltimore, and his B.S.

in Pharmacy from Massachusetts College of Pharmacy.

Lee Heeson, age 54, joined Incyte in October 2024 as Executive Vice President, Incyte International.

Prior to joining Incyte, Mr.

Heeson was Executive Vice President, Commercial International, of Seagen Inc., a biopharmaceutical company, from February 2022 to September 2024.

From February 2020 to February 2022, he was President International of Vifor Pharma Ltd., a pharmaceuticals company.

From October 2013 to January 2020, he held senior roles at Celgene Corporation, a biopharmaceutical company, most recently as President of Worldwide Markets, Inflammation & Immunology.

Earlier in his career, Mr.

Heeson held leadership positions at Galderma and Schering-Plough.

Heeson holds a B.A., with honors, from Sheffield Hallam University.

Mohamed Issa, age 42, joined Incyte in January 2025 as Executive Vice President, Head of US Oncology.

He has almost 20 years of global leadership experience in pharmaceuticals, consumer healthcare and med-tech, with expertise spanning strategy, commercialization and business development.

Before joining Incyte, he spent 13 years at Johnson & Johnson, where he held senior roles leading U.S.

Immunology, Neuroscience and Oncology businesses, most recently as Senior Vice President, US Immunology of Janssen Pharmaceuticals.

Earlier in his career, he was co-founder and CEO of a consumer healthcare company and held various roles in sales, brand management and strategy in biopharmaceuticals.

Issa holds a Pharm.D.

John’s University and an M.B.A.

in finance and economics from New York University’s Stern School of Business.

Vijay Iyengar , age 52, joined Incyte in May 2016 as Executive Vice President, Global Strategy and Corporate Development.

14 unchanged sentences

Prior to joining Incyte, she served as President from February 2018 until January 2019 and Chief Financial Officer from January 2015 to January 2019 of Unum Therapeutics Inc., a biopharmaceutical company.

From January 2014 until she joined Unum, Ms.

Stamoulis was an independent advisor to biopharmaceutical companies.

From 2009 until December 2013, Ms.

Prior to joining Unum, Ms.

Stamoulis was a Senior Vice President of Corporate Strategy and Business Development at Vertex Pharmaceuticals, Inc., a biopharmaceutical company.

7 unchanged sentences

Steven Stein, age 58, has served as Executive Vice President and Chief Medical Officer since May 2016 and joined Incyte as Senior Vice President and Chief Medical Officer in March 2015.

Prior to joining Incyte, from May 2011 to February 2015, he was the Senior Vice President, US Clinical Development & Medical Affairs at Novartis Pharmaceuticals.

Prior to joining Incyte, from May 2011 to February 2015, he was the Senior Vice President, U.S.

Clinical Development & Medical Affairs at Novartis Pharmaceuticals.

From February 2004 to April 2011, Dr.

10 unchanged sentences

in Psychology and Industrial Relations from Rockhurst University.

Matteo Trotta, age 46, joined Incyte as Executive Vice President, General Manager, Dermatology US in March 2024.

Prior to joining Incyte, Mr.

Trotta served as the Head of Novartis U.S.

Immunology, where he led a 400-person organization across dermatology, rheumatology, auto-inflammatory, rare diseases and allergy.

He additionally held leadership roles in U.S.

marketing and sales, enterprise strategy and global manufacturing and quality.

Before joining Novartis in 2012, he was an Engagement Manager at McKinsey & Company, where he served pharmaceutical and payer clients as part of their healthcare practice.

Trotta received his Engineering Degree from Politecnico di Torino, his M.S.

in Engineering from the University of Illinois Chicago, and his M.B.A.

from Columbia Business School.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 3. Legal Proceedings